Covalon Technologies (COV) Q1 2025 earnings summary

Executive summary

• Achieved fourth consecutive quarter of strong year-over-year growth and positive net income and EBITDA, with Q1 FY'25 revenue reaching $8.2M, up 75% year-over-year, driven by US Medical Consumables.

• Four straight quarters with more than CAD 7 million in revenue, a first in company history.

• Recognized as a TSX Venture Exchange Top 50 and OTCQX Best 50 company for outstanding 2024/2025 performance.

• Secured system-wide approval for ValGuard at a major US integrated delivery network, opening significant commercial opportunities.

Financial highlights

• Q1 revenue was just over $8.2M, up 75% year-over-year, with US product sales up 73% and gross profit of $5.0M (61.2% margin).

• Adjusted EBITDA reached $1.5M for Q1 and $7.8M trailing 12 months, a significant improvement from the prior year.

• Net income was $1.2M, a $2.1M improvement year-over-year; EPS was $0.04, up $0.07 year-over-year.

• Operating expenses fell to $3.7M, down from a year ago due to restructuring.

• Ended the quarter with $17.5M in cash and no debt.

Outlook and guidance

• Sequential revenue slowdown is expected to reverse in the second half of fiscal 2025, supported by customer forecasts.

• High confidence in multi-year growth opportunities, though growth is not expected to be linear.

• Focus remains on expanding hospital customer base, increasing sales per hospital, and commercial advancement.